A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Status:
Completed
Trial end date:
2019-09-02
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event
driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection
fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in
increasing the time to first occurrence of the composite of cardiovascular (CV) death or
heart failure (HF) hospitalization in participants with HFrEF.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborators:
Bayer Canadian VIGOUR Centre Duke Clinical Research Institute